EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Heterogeneity of Checkpoint Inhibitor–Associated Pneumonitis: A Multicenter Study on Inflammatory Subtypes and Clinical Outcomes

Tingyue Luo, Tiantian Liu, Weisheng Chen iD, Wei Lei, Shuquan Wei, Yan Wang, Shudong Ma, Li Lin, Junjie Xi, Zeyu Fu, Jingze Guo, Qiang Xiao und 6 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.71041 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Tingyue Luo und 17 weiteren Autor:innen. Beteiligte Einrichtung: Chronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, …. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Pneumonia, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Funding by Science and Technology Projects in Guangzhou, Basic and Applied Basic Research Foundation of Guangdong Province, President Foundation of Nanfang Hospital, Southern Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Checkpoint inhibitor–associated pneumonitis (CIP) is a serious manifestation following tumor immunotherapy, typically mediated by T lymphocytes. However, the heterogeneity in blood inflammatory profiles and its implications on clinical characteristics and outcomes for CIP remain underexplored.

Methods

This multicenter retrospective study included 113 CIP patients without pathogen infection, aiming to classify CIP based on peripheral blood immune cell percentages.

Results

We identified three inflammatory subtypes: normal type (42.5%), neutrophil type (41.6%), and eosinophil type (15.9%). The normal‐type pneumonitis primarily occurred in Grades 1–2 (79.2%), with nonspecific interstitial pneumonia radiological features, and demonstrated a significant recovery to normal lung status after effective treatment ( p < 0.001). In contrast, patients with the neutrophil type were associated with symptomatic onset ( p = 0.036), cryptogenic organizing pneumonitis on imaging ( p = 0.004), higher steroid doses (> 40 mg/day, p = 0.011), anti‐fibrotic treatments ( p = 0.007), and pneumonia‐related mortality rate was 27.7% ( p = 0.037). Eosinophil‐type pneumonitis was more common in patients with chronic pulmonary inflammation, typically Grades 1–2 (66.7%) with hypersensitivity pneumonitis patterns ( p < 0.001) and better prognosis.

Conclusion

In summary, our study reveals that CIP can be classified into normal, neutrophil, and eosinophil types, each with distinct treatment responses and prognoses. These findings underscore the importance of subtype‐specific treatment strategies and highlight the prognostic significance of early intervention in both normal and eosinophil subtypes. Trial Registration: ClinicalTrials.gov identifier: ChiCTR2200065859.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsPneumoniaNeoplasmsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedEosinophilsNeutrophilsAged, 80 and overAdult

Stichwörter der Autor:innen

blood inflammation subtypescheckpoint inhibitor–associated pneumonitisclinical characteristicsheterogeneityoutcomes

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Chronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
  • Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
  • Pulmonary and Critical Care Medicine, Shunde Hospital, Southern Medical University (The First People's Hospital of Shunde Foshan), Foshan, Guangdong, China.
  • Department of Pulmonary and Critical Care Medicine, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.
  • Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, China.
  • Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.

ORCID-Profile: Weisheng Chen, Hangming Dong

Förderung

  • Funding by Science and Technology Projects in Guangzhou
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • President Foundation of Nanfang Hospital, Southern Medical University
  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangdong Province

Zitieren

APA

Luo, T., Liu, T., Chen, W., Lei, W., Wei, S., Wang, Y., Ma, S., Lin, L., Xi, J., Fu, Z., Guo, J., Xiao, Q., Chang, X., Huang, D., Yang, S., Liu, L., Cai, S., & Dong, H. (2025). Heterogeneity of Checkpoint Inhibitor–Associated Pneumonitis: A Multicenter Study on Inflammatory Subtypes and Clinical Outcomes. Cancer Medicine. https://doi.org/10.1002/cam4.71041

Vancouver

Luo T, Liu T, Chen W, Lei W, Wei S, Wang Y, et al. Heterogeneity of Checkpoint Inhibitor–Associated Pneumonitis: A Multicenter Study on Inflammatory Subtypes and Clinical Outcomes. Cancer Medicine. 2025. doi:10.1002/cam4.71041

BibTeX
@article{Luo2025,
  author = {Luo, Tingyue and Liu, Tiantian and Chen, Weisheng and Lei, Wei and Wei, Shuquan and Wang, Yan and Ma, Shudong and Lin, Li and Xi, Junjie and Fu, Zeyu and Guo, Jingze and Xiao, Qiang and Chang, Xiaodan and Huang, Danhui and Yang, Shifang and Liu, Laiyu and Cai, Shaoxi and Dong, Hangming},
  title = {Heterogeneity of Checkpoint Inhibitor–Associated Pneumonitis: A Multicenter Study on Inflammatory Subtypes and Clinical Outcomes},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71041}
}
Kostenlos starten →